Ph 1/2 Program Initiated for Elraglusib in refractory melanoma and additional target solid tumor and heme cancers January 25, 2026
Oricell Therapeutics Announces $70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies January 18, 2026
First US Commercial Sale of KOMZIFTI™ Triggers $135M Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin December 9, 2025
Leukogene Therapeutics Receives Strategic Funding from SCRA to Accelerate Development of Cancer Immunotherapy Pipeline November 18, 2025
Kelonia Therapeutics Enters into Strategic Collaboration with Johnson & Johnson to Advance in vivo CAR-T Therapies November 9, 2025
Enrollment in cohorts 1 & 2 of GTB-3650 Ph 1 Trial in Patients with R/R CD33 Expressing Heme Malignancies Completed October 15, 2025
FDA Accepts BLA for Priority Review for Orca-T® to Treat Heme Malignancies; PDUFA date April 6, 2026 October 8, 2025
First patient dosed in trial of huCART19-IL18 cells in the treatment of heme cancers September 10, 2025
FDA IND application for ST-01156 Ph 1 trial in patients with advanced solid tumor and heme malignances August 19, 2025
RP2D in Ph 1 Study of SENTI-202 for the Treatment of R/R Heme Malignancies, Including AML, Determined August 12, 2025
Updated BEXMAB data in frontline HR-MDS shows complete remission rate substantially increased to 43% August 11, 2025
ViroCell Biologics and AvenCell Therapeutics to accelerate development of novel allogeneic CAR-T therapies for blood cancers August 5, 2025
CBX-663 nominated for the treatment of a broad range of solid tumor and heme malignancies July 29, 2025
Xenetic Biosciences Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform July 29, 2025
Dose Level 1 of ANGELICA TRIAL completed; Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Heme Malignancies July 23, 2025
